Loading data
MEDNYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 385.79 m USD | 602.46 m USD | 1.07 bn USD | 1.6 bn USD | 1.53 bn USD |
| Cost of revenue | 110.6 m USD | 157.84 m USD | 296.2 m USD | 458.16 m USD | 398.49 m USD |
| Gross profit | 275.19 m USD | 444.62 m USD | 775.85 m USD | 1.14 bn USD | 1.13 bn USD |
| Research and development expense | 4.3 m USD | 4.6 m USD | 4.6 m USD | 4.5 m USD | 4.4 m USD |
| Selling, general and administrative expense | 289.4 m USD | 441.75 m USD | 649.45 m USD | 955.61 m USD | 911.36 m USD |
| Operating profit | -14.21 m USD | 2.88 m USD | 126.4 m USD | 184.81 m USD | 216.24 m USD |
| Profit before tax | -5.64 m USD | 3.79 m USD | 128.8 m USD | 184.06 m USD | 216.13 m USD |
| Income tax expense | 13.03 m USD | 1.7 m USD | 29.38 m USD | 40.49 m USD | 52.1 m USD |
| Net income (reported basis) | -19 m USD | 2 m USD | 99 m USD | 144 m USD | 164 m USD |
| Basic earnings per share | -1.7 USD/share | 0.19 USD/share | 9.13 USD/share | 12.82 USD/share | 14.01 USD/share |
| Diluted earnings per share | -1.7 USD/share | 0.19 USD/share | 9.1 USD/share | 12.73 USD/share | 13.89 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.